N/A N=2,331 Connecting Families to Overcome Ovarian Cancer
Ovarian Cancer
Primary: Number of Survivors Using Website Access Code — 147; 202 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=201 Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
Borderline Personality Disorder
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and as Per Severity — 30; 56; 14; 37 Participants
Phase 1 N=12 A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Huntingtons Disease
Primary: Concentrations of RO7234292 in CSF (Cerebrospinal Fluid) — 197000; 372000; 933000; 6220 ng/mL
Phase 1 N=70 A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Ovarian Cancer · Breast Cancer
Primary: Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS) — 10395.085; 9676.278 ng/mL
N/A N=25 Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens
Respiratory Tract Infections
Primary: RD19 Acceptability — 1; 0; 1; 9 Participants
Early Phase 1 N=6 Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
NASH With Fibrosis
Primary: To Determine the Mass Balance Recovery After a Single Oral Dose of [14C]-Rencofilstat — 91 percentage of total radioactivity
Phase 4 N=134 Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
Ischemia
Primary: Comparison of Accuracy of ReSTE Imaging to SPECT Imaging in Diagnosis of Ischemia — 0.1538; 0.2308 proportion of participants
N/A N=10 Intent Recognition for Prosthesis Control
Amputation
Primary: Overground Self-selected Walking Speed — 0.695 Meters per second
N/A N=60 Medtronic Closed-Loop Spinal Cord Stimulation System
Low Back Pain · Leg Pain · Upper Limb Pain
Primary: Reduction in Overstimulation Sensation — 25 Participants — p=<0.001
N/A N=1,275 Health Care Workers and Mental Health
Depressive Symptoms · Anxiety · Well-Being
Primary: Depressive Symptom Score Change — 5.29; 4.65 units on a scale
N/A N=160 Development of an Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement Among Fisherfolk in Uganda
Alcohol Use Disorder · HIV-infection/Aids
Primary: Number of Participants With Hazardous Alcohol Use at Baseline, 3 and 6 Month Follow up — 41; 26; 18; 27 Participants — p=.002
N/A N=213 A Study Comparing Ceramic-on-metal Articulation to Metal-on-metal Articulation in Cementless Primary Hip Arthroplasty
Osteoarthritis
Primary: Composite Clinical Success (CCS) Rate as Defined in the Protocol — 59; 63 Participants
Phase 2 N=62 Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment — -0.48; 1.02 Percent predicted — p=0.1804
Phase 3 N=1,195 Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury
Brain Injuries
Primary: Glasgow Outcome Scale (GOS) — 189; 183; 109; 114 Participants
Phase 2 N=19 Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Histologically Positive Lesions That Are Positive on Imaging — 86 % of participants with + lesions